264 related articles for article (PubMed ID: 3525866)
1. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
Smith PH; Suciu S; Robinson MR; Richards B; Bastable JR; Glashan RW; Bouffioux C; Lardennois B; Williams RE; de Pauw M
J Urol; 1986 Sep; 136(3):619-23. PubMed ID: 3525866
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762.
de Voogt HJ; Smith PH; Pavone-Macaluso M; de Pauw M; Suciu S
J Urol; 1986 Feb; 135(2):303-7. PubMed ID: 2935644
[TBL] [Abstract][Full Text] [Related]
3. Estramustine phosphate as primary therapy for metastatic prostate cancer. Preliminary results of the University of Wisconsin trial.
Benson RC
Urology; 1984 Jun; 23(6 Suppl):69-72. PubMed ID: 6375084
[No Abstract] [Full Text] [Related]
4. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R
J Urol; 1986 Sep; 136(3):624-31. PubMed ID: 2942707
[TBL] [Abstract][Full Text] [Related]
5. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
Benson RC; Cummings K
Prog Clin Biol Res; 1989; 303():177-86. PubMed ID: 2674984
[No Abstract] [Full Text] [Related]
6. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
Hauchecorne J
Prog Clin Biol Res; 1987; 243B():229-34. PubMed ID: 3309983
[No Abstract] [Full Text] [Related]
7. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
Benson RC; Gill GM; Cummings KB
Semin Oncol; 1983 Sep; 10(3 Suppl 3):43-5. PubMed ID: 6364366
[No Abstract] [Full Text] [Related]
8. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
Nickel CJ; Morales A
Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
[TBL] [Abstract][Full Text] [Related]
9. Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762.
Smith PH; Robinson M; Richards B; Suciu S; De Pauw M; Sylvester R; Denis L
Urology; 1984 Jun; 23(6 Suppl):64-8. PubMed ID: 6375083
[No Abstract] [Full Text] [Related]
10. The EORTC Phase III trials in prostatic cancer.
Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
[No Abstract] [Full Text] [Related]
11. Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind, crossover trial for stage D prostate cancer.
Benson RC; Gill GM
Am J Clin Oncol; 1986 Aug; 9(4):341-51. PubMed ID: 3529921
[TBL] [Abstract][Full Text] [Related]
12. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer.
Murphy GP; Huben RP; Priore R
Urology; 1986 Jul; 28(1):36-40. PubMed ID: 3523938
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate.
Morales A; Nickel JC
Urology; 1985 Nov; 26(5):477-81. PubMed ID: 3904134
[TBL] [Abstract][Full Text] [Related]
14. Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol.
Daponte D; Sylvester R; De Pauw M; Fryszman A; Smith RM; Smith PH
Br J Urol; 1983 Aug; 55(4):408-12. PubMed ID: 6349745
[TBL] [Abstract][Full Text] [Related]
15. Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
Murphy GP; Slack NH; Mittelman A
Semin Oncol; 1983 Sep; 10(3 Suppl 3):34-42. PubMed ID: 6364365
[No Abstract] [Full Text] [Related]
16. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
Kalland T; Haukaas S
Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
[TBL] [Abstract][Full Text] [Related]
17. Prostatic cancer. Transcortin levels during treatment with estramustine phosphate.
Sandberg AA; Rosenthal H; Mittelman A; Murphy GP
Urology; 1975 Jul; 6(1):17-21. PubMed ID: 1145919
[TBL] [Abstract][Full Text] [Related]
18. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
[TBL] [Abstract][Full Text] [Related]
19. Estramustine phosphate therapy in carcinoma of the prostate.
Andersson L; Edsmyr F; Jönsson G; Könyves I
Recent Results Cancer Res; 1977; (60):73-7. PubMed ID: 866798
[TBL] [Abstract][Full Text] [Related]
20. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials.
de Voogt HJ; Suciu S; Sylvester R; Pavone-Macaluso M; Smith PH; de Pauw M
J Urol; 1989 Apr; 141(4):883-8. PubMed ID: 2522561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
